Abstract
Statement of Translational Relevance Our secondary analysis highlights an important role of exercise-based prehabilitation in promoting an enhanced tumour-infiltrating lymphocyte (TILs) response in patients with oesophageal adenocarcinoma undergoing neoadjuvant chemotherapy. Compared to control patients, prehabilitation exercise was associated with higher levels of CD8+ TILs, primarily consisting of NK cells. The prehabilitation exercise maintained peak cardiopulmonary fitness with increasing positive changes in peak fitness associated with higher frequencies of CD8+ TILs. Additionally, prehabilitation exercise was associated with more mature tertiary lymphoid structures (TLSs) within patient tumours. Our findings suggest that exercise during neoadjuvant chemotherapy maintains peak cardiopulmonary fitness and has an important role in promoting changes to the tumour microenvironment. A randomised study is warranted to explore whether the prescribed exercise intensity can be optimised to increase TILs and TLSs further in oesophageal adenocarcinoma patients undergoing neoadjuvant chemotherapy before surgery.
INTRODUCTION For patients with locally advanced oesophagogastric cancer, the standard of care in the UK is neoadjuvant chemotherapy (NAC) followed by surgery. Prehabilitation exercise can improve physiological function and fitness. As no studies have assessed tumour infiltrating lymphocyte (TIL) responses in humans during NAC undergoing prehabilitation, we aimed to determine whether prehabilitation increased TILs.
METHODS We enrolled 22 patients with locally advanced oesophageal cancer on a randomised control trial comparing 16 weeks of low-to-moderate intensity twice weekly supervised and thrice weekly home-based exercise (Prehab: N=11) to no prehabilitation (Control: N=11). We analysed peak cardiorespiratory fitness (
O2peak) before NAC, after 8 weeks of NAC (Post-NAC) and following 8 weeks of NAC recovery before surgery (Pre-Surgery). We assessed tumours by high-resolution multispectral immunohistochemistry (mIHC) and NanoString spatial transcriptomics.
RESULTS We observed a main effect of time [F(2,40) = 6.394, p=0.004, η2=.242] and a group x time interaction [F(2,40) = 3.445, p=0.042, η2=.147] for relative 
O2peak. This was characterised by a 9.0% ± 10.2% reduction at Post-NAC (p=0.018) for the Controls, while the Prehabilitation group maintained 
O2peak at Post-NAC (p=1.000) and increased by 9.4% ± 7.6% from Post-NAC to Pre-Surgery (p=0.010). Prehabilitation had significantly more CD8+ cells in the tumours (3.2% ± 3.3% v 1.4% ± 1.3%, p<0.001) and the stroma (3.2% ± 2.4% v 1.6% ±1.4%, p<0.001) than the Controls. Between Baseline and Post-NAC where the Prehabilitation group maintained 
O2peak better than Controls there were significant positive associations with changes in 
O2peak and the frequencies of CD8+ TILS (r=.531, p=0.016), PDL1+ cells (r=.566, p=0.009), and GrzB+ TILS (r=.592, p=0.007). When normalised to total numbers of TILs, Prehabilitation was associated with higher levels of CD56+ NK cells (p=0.0274) of which CD56dim NK cells were highest (p=0.0464). Evaluation of the presence and localisation of tumour-associated TLSs in the oesophageal tumours revealed that most TLSs were in the peritumoral regions. Prehabilitation was associated with a higher TLS cell density (p<0.001) and a non-significant smaller, less diffuse surface area (p=0.5134). Additionally, Prehabilitation tumours had more clearly defined germinal centres indicative of mature TLSs.
CONCLUSION We show that exercise training during NAC, which improves cardiorespiratory fitness, is associated with increased frequencies of TILs and maturity of TLS. These data suggest that exercise during NAC enhances the immune system, potentially as an adjunct to immunotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02950324
Funding Statement
This work was supported by Macmillan Cancer Support (5227431 [25/6/15] and 5635161 [25/10/16])
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In accordance with the Declaration of Helsinki, the protocol was approved by an independent committee (London-Bromley Research Ethics Committee), meeting guidelines of the NHS Health Research Authority (16 November 2016) and is registered at ClinicalTrials.gov (NCT02950324).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
